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TO THE EDITOR
In vivo confocal laser scanning micro-
scopy (CLSM) is a tool for obtaining
‘‘optical biopsies’’ of skin lesions at
near histological resolution. Earlier in-
vestigations have suggested that this
instrument may be useful as a surgical
guide for the controlled excisions of
cutaneous tumors and may be espe-
cially useful for lesions with poorly
defined borders (e.g., lentigo maligna
melanomas). In vivo CLSM for the
microsurgery of basal cell carcinoma
(Tannous et al., 2003; Marra et al.,
2005) and malignant melanoma (Curiel-
Lewandrowski et al., 2004; Chen et al.,
2005) have been reported.
Currently, in vivo CLSM has been
used in the reflectance mode. Tumor
detection is based on differences in the
refractive indices between normal and
malignant tissues. However, exogenous
contrast reagents may increase the de-
tail of lesions for the demarcation of
tumor margins. For example, Tannous
et al. (2003) reported that aluminum
chloride minimized the mismatch be-
tween the tissue and immersion med-
ium refractive indices and improved the
identification of basal cell carcinoma
tumor margins in patients undergoing
Mohs micrographic surgery.
In vivo CLSM can also be used in the
fluorescence mode (Li et al., 2005).
6
Tumor
*
Kidney
Heart
Lung
Spleen
Liver
Skin
0.0 0.2 0.4 0.6 0.8 1.0
% ID g–1
5
4
3
2
1
0
0 5 10 15 20 25
Time (hour)
TRITC-
Pep-1
TRITC-
Scrambled
0 10 20 30 40 50 60 70
Vss, ml
0 1 2 3 4 5
CL, ml hour–1
6 0 2 4 6 8 10
MRT, hour–1
7
%
ID
 m
l–1
Figure 1. Pharmacokinetics and biodistributions of radiolabeled TRITC peptide conjugates. (a) [125I]
TRITC-Pep-1 (red circles) and the [125I]TRITC-scrambled control (black circles) were intravenously injected
into tumor-bearing C57BL/6 mice (0.02mgkg1) and serially bled at the indicated time points. Blood
samples were measured in a g-counter, and the results were expressed as the % of injected dose per ml
(%IDml1). Results are expressed as the means7SD of three mice per group. Differences between TRITC-
Pep-1 and the TRITC-scrambled control were not significant by the two-tailed Mann–Whitney U-test
(P40.05). (b) Non-compartmental pharmacokinetic parameters for TRITC-Pep-1 (red bars) and the TRITC-
scrambled control (black bars) were estimated from the curves shown in (a) using WinNonlin software.
Abbreviations for the derived pharmacokinetic parameters are volume of distribution at steady state (Vss),
clearance (CL) and mean residence time (MRT). Values are expressed as the means7SD. Differences in the
derived pharmacokinetic parameters between TRITC-Pep-1 and the TRITC-scrambled control were not
significant by the two-tailed Mann–Whitney U-test (P40.05). (c) [125I]TRITC-Pep-1 (red bars) and the
[125I]TRITC-scrambled control (black bars) were intravenously injected into tumor-bearing C57BL/6 mice
(0.02mgkg1) and killed 16hours later. The radioactivities of tissues were measured in a g-counter after
first measuring the organ weights. Results shown are the means7SD of three mice per group and significant
differences determined using the two-tailed Mann–Whitney U-test (*Po0.05).
Abbreviations: CLSM, confocal laser scanning microscopy; GFP, green fluorescent protein
HA, hyauronan; TRITC, tetramethylrhodamine isothiocyanate
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Fluorescently labeled antibodies or
peptides are examples of contrast re-
agents for use with in vivo CLSM.
Peptides may be ideal for in vivo
imaging compared to high-molecular-
weight antibodies due to the following:
(a) peptides have quicker distribution
times allowing rapid imaging, and (b)
the short in vivo half-lives of peptides
may ensure their efficient elimination,
thus minimizing toxic side effects
(Lundqvist and Tolmachev, 2002).
Contrast reagents for the in vivo
demarcation of melanoma margins are
lacking. Hyaluronan (HA) is a glycosa-
minoglycan expressed by malignant
melanomas. Karjalainen et al. (2000)
reported that 100% of primary melano-
mas were stroma positive for HA and
70% of the same melanomas had HA
associated with the tumor cell surfaces.
Thus, HA may be a marker for mela-
nomas. Pep-1 is an HA-binding peptide
that binds strongly to cell surface HA
but weakly to HA in the extracellular
matrix (Zmolik and Mummert, 2005).
Therefore, Pep-1 may be a new contrast
reagent for demarcating melanoma
margins.
To evaluate the utility of Pep-1 as a
contrast reagent, we conjugated tetra-
methylrhodamine isothiocyanate (TRITC)
to Pep-1 (GAHWQFNALTVRGGGSY)
or a scrambled control (WRHGFALT
AVNQGGGSY) and engineered B16-F10
melanoma cells to express green fluor-
escent protein (GFP). All animal experi-
ments were approved by the Institutional
Review Board at the University of Texas
Southwestern Medical Center.
We first investigated the phar-
macokinetics and biodistributions of
TRITC-Pep-1. As shown in Figure 1a,
[125I]TRITC-Pep-1 and the [125I]TRITC-
scrambled control showed relatively
rapid clearance and similar pharmaco-
kinetics (Figure 1b). The biodistribution
of [125I]TRITC-Pep-1 showed signifi-
cantly higher binding to melanoma
tumors compared with the [125I]
TRITC-scrambled control, whereas both
peptides showed similar levels of
binding to the other tissues (Figure 1c).
These results showed that TRITC-Pep-1
bound to B16-F10 tumors with high
specificity. Next, we imaged tumors
established in mouse ear skin under
CLSM. GFPþ tumors were distinguish-
able from the surrounding tissue by
TRITC-Pep-1, but not by the TRITC-
scrambled control (Figure 2a). Because
the sizes of tumors exceeded the
microscopic field of view, we created
montages of tumor subimages. Again,
TRITC-Pep-1 showed binding to the
tumor but weak or no binding to
uninvolved tissue, whereas the TRITC-
scrambled control showed little or no
binding to either the tumor or the tissue
(Figure 2b). Importantly, TRITC-Pep-1
signals were useful for full thickness
(B1.0mm) tumor detection. The con-
trast-to-noise ratio for TRITC-Pep-1 was
significantly greater than the TRITC-
scrambled control, showing its poten-
tial utility to serve as a contrast reagent
(Figure 2c).
The merged images of the tumors
(Figure 2a and b) highlighted that
TRITC-Pep-1 staining was heteroge-
neous. We therefore made a compar-
ison of fluorescent regions in three
different tumors to assess TRITC-Pep-1
binding. We found variations in TRITC-
Pep-1 intensities between different re-
gions within the same tumor, but did
not observe a correlation between the
variations in TRITC-Pep-1 signals and
different tumor regions (i.e., midtumor
versus the tumor periphery). Because
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Figure 2. Intravital imaging and analyses of melanoma tumors in mice. (a) GFP (endogenous signals
from B16-F10 melanoma cells) and TRITC fluorescence signals from injected peptides (0.02mg kg1)
were acquired under CLSM for tumorsB3.0mm in diameter. Excitation for GFP was 488 nm and 543 nm
for the TRITC-conjugated peptides. Fluorescence emissions were detected with water immersion objectives
(original magnification  10) using sequential collections of the fluorescent signals. Three-dimensional
image stacks were recorded (axial planes were separated by 1.10 mm) using a line average of four.
Importantly, we obtained an ‘‘optical biopsy’’ for the full tumor thickness (B1.0mm). Results are
presented as the maximum intensity projections of horizontal (x–z planes) and vertical (y–z planes) scans
(Bar¼100 mm; original magnification  100). (b) Montages of tumor subimages were used to recreate the
wide fields of view. Acquisition of the tumor subimages was performed as described above except that a
line average of two was used instead of four to reduce potential photobleaching of adjacent sections
during signal collection (Bar¼1.5mm; original magnification per sub image 100). (c) The TRITC
fluorescent intensities in three different tumors established in three different mice was used to calculate
the contrast-to-noise ratios. TRITC-Pep-1 (red) showed a significantly higher contrast-to-noise ratio
compared with the TRITC-scrambled control (black). Results are presented as the means7SD (*Po0.05
by the two-tailed Mann–Whitney U-test). (d) The GFP (white) and TRITC-Pep-1 (red) mean fluorescent
intensities in square 0.1 0.1mm regions of interest in 0.5 0.5mm fields of view for three different
tumors established in three separate mice was evaluated. Five different fields per tumor were analyzed.
Results showed marked variations of both GFP and TRITC-Pep-1 fluorescent intensities between different
regions within the same tumor. On the other hand, TRITC-Pep-1 signals were detected in all of the GFPþ
regions and vice versa.
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GFP and TRITC-Pep-1 fluorescent in-
tensities were unequal in many of the
tumor regions (Figure 2d), the merged
images were not uniformly yellow as
expected for overlapping red and green
colors of equal intensities. We therefore
calculated overlap coefficients based
on overlap subcoefficients that take into
account the differences between GFP
and TRITC-Pep-1 intensities. We found
that the overlap coefficients for tumors
1, 2, and 3 were 0.976, 0.987, and
0.792, respectively. The large values for
the overlap coefficients show that
TRITC-Pep-1 had high co-registration
with the GFP signals throughout most, if
not all, of the tumor mass. How can we
explain the heterogeneous binding of
TRITC-Pep-1? Perhaps, the simplest
explanation is that regions showing
high levels of TRITC-Pep-1 staining
correspond to regions with high HA
concentrations, whereas low levels of
TRITC-Pep-1 staining correspond to
regions with low HA concentrations. It
is well known that perfusion defects in
tumors contribute to regional differ-
ences in hypoxia, anoxia, and acidosis
due to a non-homogeneous vascular
supply. Importantly, HA synthesis is a
tightly regulated process that is modu-
lated by the microenvironment. For
example, lactate (a tumor metabolite)
induces B16-F10 melanoma cells to
increase their HA synthesis (Rudrabha-
tla et al., 2006). Because lactate and
other metabolites are not uniformly
distributed throughout tumors (Walenta
et al., 2000), we speculate that high and
low levels of TRITC-Pep-1 binding
reflect regional differences in HA ex-
pression due to the heterogeneous
microenvironment of the tumors.
Can TRITC-Pep-1 be used for the
mapping of melanomas? It will be
necessary to compare the clinical,
histological, and TRITC-Pep-1 margins
in detail. Also, different human mela-
noma lines will need to be compared to
assess the general utility of TRITC-Pep-1
to serve as a probe for demarcating
melanoma margins under CLSM.
In conclusion, we have described a
probe for demarcating melanoma mar-
gins in vivo. This work differs funda-
mentally from most other peptide
contrast reagents, which have been
developed for binding protein receptors
(Becker et al., 2001; Ye et al., 2006;
Zhang et al., 2006) or are fluorescent
only after enzymatic cleavage (Mah-
mood et al., 1999; McIntyre et al.,
2004). Results herein suggest that car-
bohydrates can also serve as targets for
in vivo imaging.
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